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(CMA) based on Time-and-Motion (TM) simulations designed to
allow comparison of the complexity related to hGH preparation
and administration. METHODS: Nurses naïve to hGH adminis-
tration or similar drug-device combinations were recruited to
evaluate four hGH pen devices via TM simulations. Five video-
taped and timed trials for each product were evaluated based on
four phases: 1) Learning (initial instructions for use); 2) Prepara-
tion (arranging device for use); 3) Administration (actual injec-
tion); and 4) Storage (provide for product viability between
doses). The CMA applied costs related to parental opportunity
costs categorized as wages (U.S. Bureau of Labor Statistics aver-
ages), drugs (First Databank WAC prices), and injection supplies.
RESULTS: Two pen devices (Norditropin NordiFlex NNF, Nor-
ditropin NordiPen NNP) take less Total Time (<) to use than the
comparators (Genotropin GTP < Humatrope PenHTP, p < 0.05).
Most time savings were directly related to differences in Learning
(p < 0.05) and Preparation times (p < 0.05). Between the four
hGH devices, the NNF/NNP pens appeared easier to learn to use
than the HTP/GTP pen devices (NNF = NNP < HTP < GTP,
p < 0.05) and were also easier to prepare for use (GTP < HTP,
p < 0.05). User “learning curve” slopes decreased with practice
(p < 0.05) over the ﬁve trials. Once any product was prepared for
use, Administration and Storage times were nearly identical
(p > 0.05). Parental time cost (opportunity cost) savings were
greater in devices that were easier to Learn and Prepare for use
(NNF 16% < NNP 24% < GTP 7% < HTP). Supplies costs were
<1% of drug costs for all devices. CONCLUSIONS: Simulation-
generated data demonstrated the value of multi-dimensional
product-device analysis and revealed thatNNF andNNP took less
Total Time vs. comparators.
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OBJECTIVE: To assess differences in overall and diabetes-related
cost and utilization between diabetes patients treated with insulin
detemir and insulin glargine. METHODS: Retrospective data
analysis included commercial enrollees in a large US health plan
with medical and pharmacy beneﬁts. Patients were identiﬁed if
their ﬁrst prescription claim (index) for insulin detemir or insulin
glargine occurred between May 1, 2006 and December 31, 2006.
Eligible patients were required to have 6 months of continuous
enrollment pre- and post-index date, no evidence of insulin
detemir or insulin glargine use during pre-index and an A1C
reading during the pre-index period. Primary outcomes include
daily average consumption (DACON) of insulin detemir or
insulin glargine and overall and diabetes-related cost. Differences
in outcomes between insulin detemir and insulin glargine users
were adjusted for baseline characteristics through generalized
linear modeling (GLM). Propensity score matching was used to
reduce selection bias between the two groups. RESULTS: There
were 153 insulin detemir and 640 insulin glargine patients in the
study, with no signiﬁcant difference in age, gender and diabetes
types between the two groups. Adjusted DACON for insulin
detemir users was 34.3 units/day compared to 32.9 units/day for
insulin glargine (p = 0.51). Adjusted diabetes-related pharmacy
cost for insulin detemir users was higher than insulin glargine
patients ($1467 vs. $1255; p < 0.01). However, adjusted
diabetes-related medical cost for insulin glargine users was more
than twice that of insulin detemir users ($2304 vs. $1091;
p < 0.01). Moreover, adjusted overall medical cost for insulin
glargine users was also much higher compared to insulin detemir
patients ($7497 vs. $6221; p < 0.05). No difference in overall
pharmacy cost was observed. CONCLUSION: No signiﬁcant
difference in DACON between insulin detemir and insulin
glargine users was observed. Although insulin detemir patients
pay more for diabetes-related prescription medications, these
costs were more than offset by signiﬁcantly lower diabetes-
related and overall medical costs.
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OBJECTIVE: To examine medical conditions associated with
diabetic neuropathy (DN) and to identify drivers of health care
charges and utilization using administrative claims database.
METHODS: We studied commercially-insured individuals aged
18–64 with 24 months continuous enrollment in a national
health plan. DN patients were identiﬁed by having1 claim with
a DN diagnosis between July 2004 and June 2005. Using pro-
pensity scoring, we selected a demographically-matched control
cohort of patients with diabetes (10:1 ratio to DN). We com-
pared disease prevalence, Year 2 distribution of charges, and
reasons for ER visits and inpatient admissions between DN
patients and controls. Logistic regression was used to assess the
marginal contribution of DN to the most common reasons for
ER and inpatient admissions controlling for differences in overall
illness burden. RESULTS: Compared with controls (n = 86,550),
DN patients (n = 8655) had more unique number of co-morbid
medical conditions (9.7 vs. 6.8) and higher ($41,394 vs.
$16,983) total medical charges. Both groups had the highest
medical charges for inpatient services, followed by outpatient
hospital and pharmacy use. Compared with controls, more DN
patients had ER visits (13% vs. 9%), inpatient hospital encoun-
ters (28% vs. 13%), and longer hospitalizations (2.4 vs. 0.6
days). The top ﬁve reasons for ER visits were the same for both
groups, with nonspeciﬁc backache being the most common.
Three of the top ﬁve reasons for inpatient admissions were also
the same: coronary atherosclerosis and other chronic ischemic
heart disease, chest pain, and cellulitis. Controlling for excess
illness burden, DN patients were still at a higher risk for hospi-
talizations due to chest pain, heart failure, and cellulitis.
CONCLUSION: DN patients had signiﬁcantly more co-morbid
medical conditions, ER visits, inpatient admissions, and longer
hospitalizations than age-and-sex matched controls.
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OBJECTIVE:To examine health care expenditures and utilization
among gout patients by severity of renal disease. METHODS: A
retrospective claims analysis using commercial enrollees in a U.S.
health plan age 18, treated with pharmaceuticals for incident
gout between Janaury 1, 2002 and December 31, 2005, without
cancer. Annual health service costs and utilization were compared
by severity of renal disease (using a claims-based algorithm) with
descriptive analysis and generalized linear modeling (GLM).
RESULTS: Renal disease was evident in 745 (9%) of 8039 sub-
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jects. Mean annual costs were $18,630 (SD$40,365) and $4510
(SD$11,185) among those with and without renal disease
(p < 0.001). Subjects with renal disease had 13.03 (SD11.50)
ofﬁce visits and 0.46 (SD0.85) hospitalizations (average length of
stay of 8.63 days (SD14.60)) per year compared to 6.50 (SD7.31),
0.09 (SD0.31) and 3.63 days (SD10.36) in those without renal
disease (p < 0.001, all measures). Among subjects with renal
disease, 398 (54%), 175 (23%), and 172 (23%) were classiﬁed
with mild, moderate, and severe disease. Annual total health care
costs were $10,888 (SD$21,676), $13,692 (SD$18,114) and
$41,570 (SD$70,502) among these subjects (p < 0.001). A GLM
model adjusting for age, gender, rate of gout ﬂares, use of allopu-
rinol and Charlson comorbidity score indicated that costs were
1.89, 2.17, and 4.91 times greater among subject with mild,
moderate and severe renal impairment compared to those with no
renal disease. Subjectswithmild,moderate, and severe disease had
annual hospitalization rates of 0.25 (SD0.50); 0.58 (SD0.99); and
0.83 (SD1.16) (p < 0.001). CONCLUSION: Health care expen-
ditures and utilization among subjects with incident gout is sub-
stantially higher among those with renal disease, increasing
substantially with severity. Better management may result in
reduction in health care cost and resource utilization.
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OBJECTIVE: There are limited data on the economic impact of
mood disorders among patients with diabetic neuropathy (DN).
This study examines factors associated with health care costs
among elderly DN patients with or without depression/anxiety
(DA). METHODS: Using a retrospective cohort design and
administrative claims data, we assessed the predictors of total
health care costs over a one-year follow-up period for over-age-65
patients with 1+ diagnosis of DN. The index date was deﬁned as
the ﬁrst observed medical claim with a diagnosis for DN in 2005.
Patients with continuous eligibility for 12 months prior to and
following the index date were included. Two cohorts of patients
were constructed for individuals with DA (DN-DA) or without
(DN-only).Multivariate linear regressionwas performed to assess
whether DN-DA patients have higher health care costs than
DN-only patients, controlling for demographic and clinical char-
acteristics (diabetes-related comorbidities and treatment regimen
for diabetes observed within 12 months prior to index date).
RESULTS: We identiﬁed 16,831 DN-only patients, and 1699
DN-DA patients. The DN-only and DN-DA groups were similar
by age (75.6 vs 75.4, p = 0.44), but DN-DA patients were more
likely to be female (56% vs. 47%, p < 0.01). DN-DA patients had
higher prevalence of diabetes-related comorbidities for cardiovas-
cular disease, nephropathy, neuropathy, obesity, and hypoglyce-
mic events than DN-only patients (all p < 0.01). Controlling for
differences in demographic and clinical characteristics, DN-DA
patients had $9785 (p < 0.01) higher total health care costs than
patients with DN-only. Factors associated with increased costs
included insurance type, geographical region, diabetes-related
comorbidities, and insulin therapy. CONCLUSION: These ﬁnd-
ings indicate that the health care costs were signiﬁcantly higher for
DN patients with depression/anxiety relative to those without
these mood disorders.
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OBJECTIVE: Diabetic neuropathy (DN) is one of the most
common complications associated with diabetes. Other diabetes-
related complications include depression, cardiovascular disease,
stroke, renal complications, skin problems, visual impairment,
and amputation. This study assesses the prevalence of other
diabetes-related complications and its marginal contribution on
medical charges among DN patients. METHODS: Commercially
insured patients aged 18–64 with at least 1 claim of DN anytime
between July 2004 and June 2005 (Year 1) enrolled in a large
health plan were selected. A demographically-matched control
cohort of patients with diabetes was constructed via propensity
scoring with a 10:1 ratio to DN cohort. Both DN patients and
controls had 12 months of continuous enrollment in both Year 1
and Year 2 (July 2005-June 2006). The prevalence of other
diabetes-associated complications was compared between DN
patients and controls. Using multivariate regressions, we exam-
ined the marginal contribution of1 other diabetes-related com-
plications on Year 2 medical charges for both cohorts controlling
for comorbidities. We also assessed the impact of DN on medical
charges.RESULTS: Fewer DN patients (11% out of 8655) had no
other diabetes-related complications than controls (24% out of
86,550). Prevalence was statistically higher for all other diabetes-
related complications in the DN group than in the control cohort
with heart disease being the most common in both groups (76%
for DN vs. 68% for controls). Controlling for comorbidities,
patients with 1 other diabetes-related complications had statis-
tically higher pharmacy and total medical charges for both DN
and controls. Charges were also higher for DN patients among
thosewith orwithout other diabetes-related complications.CON-
CLUSION: DN can occur in absence of other diabetes-related
complications. DN and other diabetes-related complications have
signiﬁcant impact on medical charges.
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OBJECTIVE: To identify factors associated with high health care
charges in patients diagnosed with diabetic neuropathy (DN).
METHODS: Data were extracted from a large, commercial
health plan database between July 2004 and June 2006. Patients
aged 18–64 were selected if they had a DN diagnosis (ICD9:
357.2x; 250.6x) between July 2004 and June 2005 (Year 1) and
were continuously enrolled over the study period. High (low)
charges groups were constructed for patients in the top and
bottom decile of annual charges. Comorbidities in Year 1 were
identiﬁed, and total charges in Year 2 (July 2005-June 2006)
were examined. Logistic regression was used to identify factors
associated with high charges. The factors considered were age,
gender, type of health plan, and other comorbidities. RESULTS:
A total of 8655 DN patients (mean age 51 years, 46% female)
were included in the study. Compared to the low charges group,
patients in the high charges group had signiﬁcantly more unique
number of co-morbid medical conditions (16 vs. 10) and higher
charges ($231,898 vs. $20,213) (both p < 0.001). The high
charges group contributed 56% of the total charges of all DN
patients. Factors signiﬁcantly (p < 0.001) contributing to high
charges included dialysis status (OR = 19.2),metastatic cancer
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